Causal Forests Versus Inverse Probability of Treatment Weighting to Adjust for Cluster‐Level Confounding: A Parametric and Plasmode Simulation Study Based on US Hospital Electronic Health Record Data
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70257 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Mike Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaco- and Device Epidemiology Group, Health Data Sciences, Botnar Research Centre, NDORMS, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Electronic Health Records, Product Surveillance, Postmarketing. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson Ltd..
Abstract (Originalsprache)
Background
Rapid innovation and new regulations increase the need for post‐marketing surveillance of implantable devices. However, complex multi‐level confounding related to patient‐level and surgeon or hospital covariates hampers observational studies of risks and benefits. We conducted two simulation studies to compare the performance of Causal Forests (CF) versus Inverse Probability of Treatment Weighting (IPTW) to reduce confounding bias in the presence of strong surgeon impact on treatment allocation.
Methods
Two Monte Carlo simulation studies were carried out: (1) Parametric simulations with patients nested in clusters (ratio 10:1, 50:1, 100:1, 200:1, 500:1) and sample size n = 10 000 were conducted with patient and cluster level confounders; (2) Plasmode simulations generated from a cohort of 9981 patients admitted for pancreatectomy between 2015 and 2019 from the US PINC AT hospital research database. Different CF algorithms and IPTW were used to estimate binary treatment effects.
Results
Performance varied with the strength of cluster‐level confounding. Under weak to moderate surgeon influence, CF and IPTW performed similarly. When confounding was strong (OR = 2.5), CF reduced bias compared with IPTW: in parametric simulations, relative bias averaged 11.2% for CF versus 19.9% for IPTW, with similar advantages observed in plasmode simulations.
Conclusions
CF shows promise as a method for estimating treatment effects in scenarios where cluster‐level confounding strongly impacts treatment allocation. More research is needed to guide its use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmaco- and Device Epidemiology Group, Health Data Sciences, Botnar Research Centre, NDORMS, University of Oxford, Oxford, UK.
- Epidemiology & Real-World Data Sciences, MedTech, Johnson & Johnson, New Brunswick, New Jersey, USA.
- Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Rheinland-Pfalz, Germany.
- Department of Medical Informatics, Erasmus Medical Center University, Rotterdam, the Netherlands.
ORCID-Profile: Daniel Prieto-Alhambra
Förderung
- Johnson & Johnson Ltd.
Zitieren
APA
Du, M., Johnston, S., Coplan, P. M., Strauss, V. Y., Khalid, S., & Prieto-Alhambra, D. (2025). Causal Forests Versus Inverse Probability of Treatment Weighting to Adjust for Cluster‐Level Confounding: A Parametric and Plasmode Simulation Study Based on US Hospital Electronic Health Record Data. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70257
Vancouver
Du M, Johnston S, Coplan PM, Strauss VY, Khalid S, Prieto-Alhambra D. Causal Forests Versus Inverse Probability of Treatment Weighting to Adjust for Cluster‐Level Confounding: A Parametric and Plasmode Simulation Study Based on US Hospital Electronic Health Record Data. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70257
BibTeX
@article{Du2025,
author = {Du, Mike and Johnston, Stephen and Coplan, Paul M and Strauss, Victoria Y and Khalid, Sara and Prieto-Alhambra, Daniel},
title = {Causal Forests Versus Inverse Probability of Treatment Weighting to Adjust for Cluster‐Level Confounding: A Parametric and Plasmode Simulation Study Based on US Hospital Electronic Health Record Data},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70257}
}
EUVIMED